Gene
PALB2
PALB2 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (14), Actionable biomarkers (8), Trial mentions (229), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention PALB2. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 3 with a planned future start.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 16 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 19 of 8,738 | 0.22% | not measured | |
| 2025 | 22 of 8,875 | 0.25% | not measured | |
| 2024 | 17 of 8,597 | 0.20% | not measured | |
| 2023 | 22 of 8,275 | 0.27% | 38 of 11,460 | 0.33% |
| 2022 | 30 of 8,285 | 0.36% | 56 of 13,598 | 0.41% |
| 2021 | 21 of 8,692 | 0.24% | 54 of 15,045 | 0.36% |
| 2020 | 30 of 7,640 | 0.39% | 31 of 14,459 | 0.21% |
| 2019 | 21 of 7,300 | 0.29% | 30 of 12,159 | 0.25% |
| 2018 | 15 of 6,927 | 0.22% | 27 of 11,854 | 0.23% |
| 2017 | 7 of 6,558 | 0.11% | 14 of 11,595 | 0.12% |
Showing 10 of 37 years.
Assay-provider ledger (14)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Agilent Technologies | Reagent supplier | Clinical validation | 1 | July 15, 2025 |
| Illumina | Unclassified | Clinical validationAnalytical validation | 3 | July 15, 2025 +1 undated |
| QIAGEN | Reagent supplier | Clinical validation | 1 | July 15, 2025 |
| TWIST Bioscience | Reagent supplier | Clinical validation | 1 | July 15, 2025 |
| New Amsterdam Genomics, Inc. | Diagnostic provider | Clinical validationAnalytical validation | 1 | March 01, 2020 |
Showing 5 of 14 assay-provider companies.
Actionable biomarkers (8)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| PALB2 deletion | Parp Inhibitors | response-associated | pancreatic carcinoma | Cancer Genome Interpreter |
| PALB2 oncogenic mutation | Platinum Agent | response-associated | pancreatic carcinoma | Cancer Genome Interpreter |
| PALB2 deletion | Platinum Agent | response-associated | pancreatic carcinoma | Cancer Genome Interpreter |
| PALB2 deletion | Mytomycin C | response-associated | pancreatic carcinoma | Cancer Genome Interpreter |
| PALB2 oncogenic mutation | Mytomycin C | response-associated | pancreatic carcinoma | Cancer Genome Interpreter |
Showing 5 of 8 actionable-biomarker assertions.
Trial mentions (229)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT06403904 | Trial biospecimen (AACT) |
| NCT07532434 | Trial biospecimen (AACT) |
| NCT05501548 | Trial eligibility (AACT) |
| NCT04584255 | Trial eligibility (AACT) |
| NCT03318445 | Trial eligibility (AACT) |
Showing 5 of 229 trial mentions.
Target-disease associations (289)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Ampulla of Vater Carcinoma | cancer or benign tumor | Cancer Gene Census |
| Anaplastic (Malignant) Meningioma | cancer or benign tumor | Cancer Gene Census |
| Appendix Goblet Cell Carcinoid | cancer or benign tumor | Cancer Gene Census |
| Atypical Endometrial Hyperplasia | cancer or benign tumor | Cancer Gene Census |
| Benign Adrenal Gland Pheochromocytoma | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 289 associations.
Vendor sourcing (915)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is not observed in the gnomAD v4.1.0 dataset. Predicted Consequence/Location: Stop-gained (nonsense): predicted to result in a loss or disruption... | View ClinVar record SCV006581759.1 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The PALB2 c.1684+1G>A variant (rs1555461148), also known as 1559+1G>A, is reported in the literature in individuals with breast cancer (Yang 2017, Zhou 2020)... | View ClinVar record SCV004563614.1 |
| AbbVie Inc. | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Patients must have a histologically documented (either primary or metastatic site) diagnosis of advanced solid tumor cancer (stage IV or unresectable) o... | View trial NCT03061188 |
| AbbVie Inc. | Trial collaborator | Mentioned in trial textTrial free-text mention | PALB2 | View trial NCT03061188 |
| Abramson Cancer Center | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : * Prior treatment with a PARP inhibitor, ipilimumab, or other cytotoxic T-lymphocyte-associated-4 protein (CTLA-4) inhibitor. * Patients who have demonstr... | View trial NCT06747845 |
Showing 5 of 915 sourcing records.
Trial-cited literature (325)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in <i>PALB2</i> or Somatic Mutations in <i>BRCA1</i> or <i>BRCA2</i>. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2026 | 3 |
| Cancer of the ovary, fallopian tube, and peritoneum: 2025 update. | International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics | 2025 | 27 |
| Phase II Study of Niraparib in Patients With Advanced Melanoma With Homologous Recombination Pathway Gene Mutations. | JCO precision oncology | 2025 | 9 |
| Germline Pathogenic Variants Among Women Without a History of Breast Cancer: A Secondary Analysis of the WISDOM Randomized Clinical Trial. | JAMA internal medicine | 2025 | 5 |
| Estimands for Clinical Effectiveness of Risk-Reducing Early Salpingectomy in Women With High Risk of Ovarian Cancer. | JAMA network open | 2025 | 4 |
Showing 5 of 325 papers.
Protein variant mentions (471)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A1079V | 1 | 2015 | PMID 25741868 |
| p.A1138T | 1 | 2016 | PMID 26467025 |
| p.A188G | 2 | 2015 to 2017 | PMID 28873162, PMID 25741868 |
| p.A503P | 1 | 2015 | PMID 25741868 |
| p.A587T | 1 | 2015 | PMID 25741868 |
Showing 5 of 471 variants.
Literature-extracted relations (52)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Platinum | Chemical | associate |
Reflex Testing for Germline <i>BRCA1</i>, <i>BRCA2</i>, <i>PALB2</i>, and <i>ATM</i> Mutations in Pancreatic Cancer: Mutation Prevalence and Clinical Outcomes From Two Canadian Research Registries. | 2018 |
| Breast Neoplasms | Disease | associate |
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in <i>PALB2</i> or Somatic Mutations in <i>BRCA1</i> or <i>BRCA2</i>. | 2026 |
| Breast Neoplasms | Disease | associate |
Germline Pathogenic Variants Among Women Without a History of Breast Cancer: A Secondary Analysis of the WISDOM Randomized Clinical Trial. | 2025 |
| Neoplasms | Disease | associate |
LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes. | 2025 |
| Carcinoma, Pancreatic Ductal | Disease | associate |
Should We Offer Universal Germline Genetic Testing to All Patients with Pancreatic Cancer? A Multicenter Study. | 2024 |
Showing 5 of 52 relation assertions.
Organizations publishing (478)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 31 | 2015 to 2026 |
| Government of the United States of America | Government | 20 | 2014 to 2023 |
| Dana-Farber Cancer Institute | Other | 19 | 2017 to 2026 |
| University of Washington | Academic | 14 | 2015 to 2025 |
| The University of Texas System | Academic | 13 | 2015 to 2023 |
Showing 5 of 478 organizations.
Where PALB2 appears
- cancer or benign tumor
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- measurement
- phenotype
223 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.